Zacks Investment Research Downgrades Chiasma (NASDAQ:CHMA) to Hold

Zacks Investment Research cut shares of Chiasma (NASDAQ:CHMA) from a buy rating to a hold rating in a research report released on Wednesday morning, Zacks.com reports.

According to Zacks, “Chiasma, Inc. is a biopharmaceutical company. The company’s TPE(R) technology develops oral peptides and other molecules. Its primary product candidate consists of oral octreotide which is in different clinical trial. Chiasma, Inc. is based in Newton, USA. “

Several other equities analysts also recently commented on the stock. Cantor Fitzgerald set a $18.00 price objective on shares of Chiasma and gave the company a buy rating in a research note on Friday, June 28th. HC Wainwright downgraded shares of Hydrogenics from a buy rating to a neutral rating in a research note on Friday, June 28th. One analyst has rated the stock with a hold rating and five have issued a buy rating to the company’s stock. Chiasma presently has a consensus rating of Buy and an average price target of $12.94.



Shares of NASDAQ:CHMA opened at $6.44 on Wednesday. The company has a market capitalization of $209.67 million, a P/E ratio of -5.03 and a beta of 1.20. The company’s 50-day moving average price is $7.40. Chiasma has a 12 month low of $1.20 and a 12 month high of $8.29.

Chiasma (NASDAQ:CHMA) last issued its quarterly earnings data on Thursday, May 9th. The biotechnology company reported ($0.36) EPS for the quarter, missing the consensus estimate of ($0.34) by ($0.02). On average, equities research analysts forecast that Chiasma will post -1.14 earnings per share for the current year.

In related news, Director Roni Mamluk sold 10,000 shares of the stock in a transaction dated Tuesday, April 16th. The shares were sold at an average price of $5.31, for a total value of $53,100.00. Following the completion of the transaction, the director now directly owns 10,000 shares of the company’s stock, valued at $53,100. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Corporate insiders own 6.20% of the company’s stock.

Hedge funds have recently added to or reduced their stakes in the stock. Millennium Management LLC bought a new position in Chiasma in the fourth quarter worth about $41,000. Acadian Asset Management LLC raised its stake in Chiasma by 99.1% in the fourth quarter. Acadian Asset Management LLC now owns 22,647 shares of the biotechnology company’s stock worth $70,000 after buying an additional 11,273 shares in the last quarter. Tibra Equities Europe Ltd bought a new position in Chiasma in the first quarter worth about $200,000. Deutsche Bank AG raised its stake in Chiasma by 27.8% in the fourth quarter. Deutsche Bank AG now owns 78,198 shares of the biotechnology company’s stock worth $243,000 after buying an additional 16,996 shares in the last quarter. Finally, Dimensional Fund Advisors LP raised its stake in Chiasma by 20.6% in the fourth quarter. Dimensional Fund Advisors LP now owns 97,644 shares of the biotechnology company’s stock worth $304,000 after buying an additional 16,658 shares in the last quarter. 62.78% of the stock is owned by institutional investors.

Chiasma Company Profile

Chiasma, Inc, a clinical-stage biopharmaceutical company, focuses on developing oral medications using transient permeability enhancer technology platform for the treatment of rare and serious chronic disease in the United States, Europe, and internationally. The company offers oral octreotide capsules for adult patients under the MYCAPSSA name, which is in two Phase III clinical trials for the treatment of acromegaly, a condition that results in the body's production of excess growth hormone.

Read More: What is the CBOE Russell 2000® Volatility Index?

Get a free copy of the Zacks research report on Chiasma (CHMA)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Chiasma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Chiasma and related companies with MarketBeat.com's FREE daily email newsletter.